Physician profile
Nicholas E Sward
NPI 1447220918
$2,303.47
in general payments reported to CMS, 2019-2025
31 companies · $50.41 in 2025
The $50.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $126 · 2021: $113 · 2022: $74.88 · 2023: $557 · 2024: $829 · 2025: $50.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $587.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $174.58 | 2019-2024 | |
| Amgen INC. | $147.70 | 2019-2024 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $128.48 | 2019-2024 | Farxiga, Airsupra |
| Abbvie INC. | $107.19 | 2019-2024 | Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $101.86 | 2019-2024 | Gardasil 9, Proquad, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.02 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $86.62 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Insulet Corporation | $82.32 | 2023-2024 | Omnipod |
| Novartis Pharmaceuticals Corporation | $75.64 | 2023-2025 | |
| Abbott Laboratories | $69.26 | 2023-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $64.93 | 2019 | |
| Astellas Pharma US INC | $54.82 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $52.77 | 2023-2024 | Shingrix, Arexvy |
| Dexcom, INC. | $48.55 | 2024 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $46.65 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.95 | 2019-2024 | Xifaxan |
| Inspire Medical Systems, INC. | $40.76 | 2024 | Inspire |
| Shire North American Group INC | $34.40 | 2019 | |
| Axsome Therapeutics, INC. | $33.03 | 2023 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $29.77 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $26.34 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $26.03 | 2019 | |
| Daiichi Sankyo INC. | $22.85 | 2019 | |
| Biomarin Pharmaceutical INC. | $21.28 | 2024 | Voxzogo 1.2mg |
| Ironshore Pharmaceuticals INC. | $20.20 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.92 | 2024 | Uptravi, Opsumit |
| Exact Sciences Corporation | $16.56 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $14.59 | 2019 | |
| Phadia US INC. | $13.85 | 2024 | Immunocap |
| Idorsia Pharmaceuticals US INC | $13.56 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Sward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.